← Human Trials & Peer-Reviewed Studies
Increased plasma levels of glucose-dependent insulinotropic polypeptide are associated with decreased postprandial energy expenditure after modern Japanese meals
Plain-language guide to PMID 27112963 (2017): crossover randomized controlled trial study of GIP (Gastric Inhibitory Polypeptide) and Ghrelin in 1, men.
Key Facts
- PMID
- 27112963
- Journal
- European journal of nutrition
- Year
- 2017
- Study type
- Randomized Controlled Trial
- Authors
- Osaki N et al. (5 authors)
- DOI
- 10.1007/s00394-016-1216-y
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at GIP (Gastric Inhibitory Polypeptide) and Ghrelin.
This study aimed to clarify the effects of these nutritional changes on postprandial energy expenditure and the release of metabolism-regulating hormones.
Who Took Part
According to the abstract, 1, men were involved.
PubMed indexes the participants as adults, men only.
In experiment 1, nine healthy Japanese men participated in a crossover study during which they ingested a test diet comprising three meals; postprandial blood parameters were measured after each meal.
In experiment 2, another ten men participated in a crossover study during which they ingested 2 meals, after which metabolic responses and blood variables were evaluated.
How the Study Was Run
In design terms this was a randomized and crossover study.
Because people in this GIP (Gastric Inhibitory Polypeptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
In the crossover set-up each of the men took both GIP (Gastric Inhibitory Polypeptide) and the comparison in turn, acting as their own control.
What Was Measured
The subject headings attached to it are Asian People, Blood Glucose, Body Mass Index, Cholecystokinin, Diet, Dietary Carbohydrates and Dietary Fats.
Author keywords: Gastrointestinal hormones, Ghrelin, Glucose-dependent insulinotropic polypeptide, Japanese meal and Postprandial energy expenditure.
What This Means in Plain Language
The paper is a randomized and crossover study of GIP (Gastric Inhibitory Polypeptide) and Ghrelin in 1, men.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2017 (European journal of nutrition), a journal based in Germany.
More context: the GIP (Gastric Inhibitory Polypeptide) compound page and the Ghrelin compound page, all human trials.
Our Notes on the Compounds
GIP (Gastric Inhibitory Polypeptide): A 42-amino-acid gut hormone that boosts insulin release after meals; one of the two receptors tirzepatide acts on.
Ghrelin: A 28-amino-acid stomach hormone that signals hunger and triggers growth hormone release; studied in human trials as an infusion.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.